A Phase 3 interventional study of Anifrolumab and placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 65 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 9 in phase 3, and was the 8th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2021.
This study's enrollment of 277 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 9th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2021, is one of 9 in phase 3, and was the 14th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
This is a Phase III, multicenter, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg anifrolumab versus placebo in participants with moderate to severe, autoantibody positive SLE while receiving SOC treatment. The study will be performed in participants aged 18 to 70 years of age.
Participants with a confirmed diagnosis of moderate to severe active SLE and are currently receiving SOC comprising of oral corticosteroids (OCSs) and/or antimalarial, and/or immunosuppressants, either alone or any combination of them, for a required duration of treatment at a stable dose, as described in the inclusion criteria shall be included. Participants must have eligible scores for SLEDAI-2K, BILAG-2004, and PGA as confirmed by the DACRT.
Eligible participants will be randomised in a 1:1 ratio to receive either a fixed intravenous dose of 300 mg anifrolumab plus SOC or placebo plus SOC every 4 weeks (Q4W) for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit.
Key inclusion criteria:
Must be receiving at least one of the following SOC regimens at screening:
Key exclusion criteria:
Receipt of any of the following:
16. Certain laboratory test results requirements. 17. Concurrent enrolment in another clinical study. 18. History or current alcohol, drug or chemical abuse within 1 year. 19. Major surgery within 8 weeks or planned elective major surgery.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
Drug: placebo
Anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48. Each dose must be at least 14 days apart.
Biological: Anifrolumab
Intravenous infusion (IV)
Intravenous infusion (IV)
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo
Composite endpoint (BICLA),a composite binary endpoint defined by meeting all of the following criteria: * Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of ≥0.30 points on a 3-point PGA visual analogue scale (VAS)
Time frame: Week 52
The Proportion of Participants Who Achieve SRI(4) Response at Week 52
SRI(4) response defined by meeting all of the following criteria: * Reduction from baseline of ≥ 4 points in the SLEDAI-2K; * No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline; * No worsening from baseline in the participants' lupus disease activity defined by an increase ≥0.30 points on a 3-point PGA VAS;
Time frame: Week 52
The Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day
Maintained OCS reduction defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52
Time frame: Week 52
Annualized Flare Rate Through Week 52
Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit
Time frame: Week 52
| Milestone | Anifrolumab 300mg | Placebo |
|---|---|---|
| Started | 138 | 139 |
| Started treatment | 138 | 138 |
| Completed | 118 | 113 |
| Not completed | 20 | 26 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Lack of efficacy | 1 | 9 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 7 |
| Withdrew: Due to other reasons not listed | 9 | 6 |
| Withdrew: Randomised, not treated | 0 | 1 |
Composite endpoint (BICLA),a composite binary endpoint defined by meeting all of the following criteria: * Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of ≥0.30 points on a 3-point PGA visual analogue scale (VAS)
| Participants | Anifrolumab 300mg | Placebo |
|---|---|---|
| Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo | 84 | 46 |
SRI(4) response defined by meeting all of the following criteria: * Reduction from baseline of ≥ 4 points in the SLEDAI-2K; * No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG-2004 B items compared to baseline; * No worsening from baseline in the participants' lupus disease activity defined by an increase ≥0.30 points on a 3-point PGA VAS;
| Participants | Anifrolumab 300mg | Placebo |
|---|---|---|
| The Proportion of Participants Who Achieve SRI(4) Response at Week 52 | 90 | 50 |
Maintained OCS reduction defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52
| Participants | Anifrolumab 300mg | Placebo |
|---|---|---|
| The Proportion of Participants Who Achieve an Oral Corticosteroid (OCS) Dose ≤7.5 mg/Day at Week 40, Which is Maintained Through Week 52 in the Subgroup of Those With Baseline OCS ≥10 mg/Day | 65 | 43 |
Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit
| Flares per person-years | Anifrolumab 300mg | Placebo |
|---|---|---|
| Annualized Flare Rate Through Week 52 | 0.22 | 0.51 |
Collected over From date of first dose of investigational product throughout the treatment period up to the final clinical database locks (10JUN2025) and the safety follow-up period (until 84 days following the date of last investigational product dose). Maximum timeframe of 60 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anifrolumab 300mg | 0/138 (0%) | 30/138 (21.7%) | 119/138 (86.2%) |
| Placebo | 0/138 (0%) | 17/138 (12.3%) | 115/138 (83.3%) |
| Event | Anifrolumab 300mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 5/138 | 2/138 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 2/138 | 4/138 |
| GastroenteritisInfections and infestations | 2/138 | 0/138 |
| Pneumonia bacterialInfections and infestations | 2/138 | 0/138 |
| Upper respiratory tract infectionInfections and infestations | 0/138 | 2/138 |
| Urinary tract infectionInfections and infestations | 0/138 | 2/138 |
| Herpes zosterInfections and infestations | 1/138 | 0/138 |
| Herpes zoster cutaneous disseminatedInfections and infestations | 1/138 | 0/138 |
| Meningitis viralInfections and infestations | 0/138 | 1/138 |
| Ophthalmic herpes zosterInfections and infestations | 1/138 | 0/138 |
| Event | Anifrolumab 300mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 64/138 | 51/138 |
| Covid-19Infections and infestations | 20/138 | 15/138 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/138 | 13/138 |
| Herpes zosterInfections and infestations | 9/138 | 1/138 |
| Urinary tract infectionInfections and infestations | 2/138 | 9/138 |
| HypokalaemiaMetabolism and nutrition disorders | 5/138 | 9/138 |
| PyrexiaGeneral disorders | 5/138 | 9/138 |
| NasopharyngitisInfections and infestations | 7/138 | 5/138 |
| ToothacheGastrointestinal disorders | 7/138 | 1/138 |
| GastroenteritisInfections and infestations | 6/138 | 6/138 |
The full analysis set (FAS): All participants randomized into the study who receive at least 1 dose of investigational product.
| Age, Continuous(Years) | Anifrolumab 300mg | Placebo | Total |
|---|---|---|---|
| Mean | 36.2 ± 9.7 | 36.1 ± 9.8 | 36.1 ± 9.8 |
| Age, Customized(Participants) | Anifrolumab 300mg | Placebo | Total |
|---|---|---|---|
| Age group — >=18 to <65 years | 137 | 137 | 274 |
| Age group — >=65 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Anifrolumab 300mg | Placebo | Total |
|---|---|---|---|
| Female | 128 | 126 | 254 |
| Male | 10 | 12 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Anifrolumab 300mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 138 | 138 | 276 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Anifrolumab 300mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 138 | 138 | 276 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2021 to primary completion in Apr 2025, 42 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 42 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →